Immutep Highlights Key Clinical Findings at ESMO Congress 2025
Immutep's Significant Presentations at ESMO Congress 2025
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a prominent name in immunotherapy for cancer and autoimmune diseases, is excited to share that three of its abstracts related to clinical trials have been accepted for presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025. This prestigious event will be held in Berlin, showcasing influential research in the oncology field.
Key Details of the Presentations
A Proffered Paper oral presentation will highlight findings from a pivotal Phase II trial known as EFTISARC-NEO, which explores the combination of eftilagimod alfa, pembrolizumab, and radiotherapy for treating patients with resectable soft tissue sarcoma. Furthermore, findings from the INSIGHT-003 trial, focusing on first-line non-small cell lung cancer (NSCLC), will be presented in a poster session. An essential abstract about the TACTI-004 Phase III trial concerning advanced/metastatic NSCLC will be shared as well.
Details of Presentations
Here are some specifics regarding the scheduled presentations:
- Title: EFTISARC-NEO: A Phase II study of neoadjuvant eftilagimod alpha, pembrolizumab, and radiotherapy in patients with resectable soft tissue sarcoma
- Presenter: Katarzyna Kozak, M.D., Ph.D., Maria Sklodowska-Curie National Research Institute of Oncology
- Session Category: Proffered Paper
- Session Title: Sarcoma
- Presentation #: 2686O
- Date and Time: 19 October 2025, 16:30 – 18:00 PM CET
Further Insights from Clinical Trials
Another presentation will include the latest updates from the INSIGHT-003 trial which examines the impact of eftilagimod alpha combined with first-line chemo-immunotherapy in metastatic non-squamous NSCLC. The details are as follows:
- Title: Eftilagimod alpha combined with 1st line chemo-immunotherapy in metastatic NSCLC – Updates from INSIGHT-003 (IKF614)
- Presenter: Dr. Akin Atmaca, Krankenhaus Nordwest, UCT-University Cancer Center
- Session Category: Poster
- Session Title: NSCLC, metastatic
- Presentation #: 1857P
- Date and Time: 18 October 2025, 12:00 – 12:45 PM CET
Innovative Approaches Harnessing Immunotherapy
A third and critical presentation will cover TACTI-004, a Phase III trial aiming to evaluate the combination of eftilagimod alfa plus pembrolizumab and chemotherapy versus placebo with pembrolizumab and chemotherapy in the context of advanced or metastatic NSCLC.
- Title: TACTI-004, a Phase 3 trial of eftilagimod alfa plus pembrolizumab + chemotherapy vs placebo + pembrolizumab + chemotherapy in 1st line advanced/metastatic NSCLC
- Presenter: Prof. Hans-Georg Kopp, Robert Bosch Hospital
- Session Category: ePoster
- Session Title: NSCLC, metastatic
- Presentation #: 2086eTiP
Significance of Proffered Papers
Proffered Papers are recognized as presentations of high-quality original data, followed by expert discussions, making them a highlight of any major conference. It's an incredible opportunity for Immutep to showcase its commitment to advancing cancer treatment.
Access to Research Findings
The abstracts will be accessible on the ESMO website, ensuring that the findings from these trials reach a broader audience. Additionally, Immutep plans to publish the posters in the Posters & Publications section of its website once the presentations are concluded.
About Immutep
Immutep is at the forefront of developing innovative immunotherapies aimed at treating cancer and autoimmune diseases. The company focuses on therapeutics related to Lymphocyte Activation Gene-3 (LAG-3) and is dedicated to harnessing its potential to modify immune responses effectively. With a broad portfolio, Immutep continues to strive for enhancing treatment options available to patients and maximizing value for its investors.
Contact Details for Media Inquiries
Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com
U.S. Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com
Frequently Asked Questions
What are the main focuses of Immutep Limited?
Immutep Limited primarily focuses on developing immunotherapy treatments for cancer and autoimmune diseases, particularly utilizing LAG-3 technology.
Where will the ESMO Congress take place?
The ESMO Congress 2025 will be held in Berlin.
What is the significance of Proffered Paper presentations?
Proffered Papers are considered high-quality original data presentations, offering insights into advanced research and facilitating expert discussions.
How can interested parties access the clinical trial findings?
Abstracts will be available on the ESMO website, and presentations will also be accessible on Immutep's website after the event.
Who can be contacted for media inquiries about Immutep?
For media inquiries in Australia, contact Eleanor Pearson; in the U.S., reach out to Chris Basta.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.